Back

BigThink revenue surges 235% to 5.6 billion won in 2026 first half

Verifying
  • BigThink Therapeutics reported first-half revenue growth driven by oncology products and overseas sales.
  • 5.6 billion won exceeded the company’s cited 5.1 billion-won full-year 2024 revenue.
  • BigThink Managing Director Kim Man-ki said annual revenue is expected to exceed 10 billion won.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.